<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679484</url>
  </required_header>
  <id_info>
    <org_study_id>DSE-866-45</org_study_id>
    <secondary_id>2007-003060-22 EUDRACT Number</secondary_id>
    <nct_id>NCT00679484</nct_id>
  </id_info>
  <brief_title>Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24</brief_title>
  <acronym>OLMEBNP</acronym>
  <official_title>A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Europe, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare olmesartan medoxomil to candesartan cilexetil in reducing BNP, a
      prognostic biomarker of heart failure, at week 24
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of subject recruitment
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute BNP change from week 0 to 24 of treatment</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of BNP responders at week 4, 8, 16 and 24 (BNP levels reduced to 350 pg/ml or less at all time points)</measure>
    <time_frame>24 weeks maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP change from week 0 to week 4, 8, and 16</measure>
    <time_frame>16 weeks maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of critical events at 24 weeks: All cause death; Cardiovascular death defined as death due to: HF, myocardial infarction, cardiac arrhythmia, stroke/cerebral vascular accident, other cardiovascular cause (e.g., aneurysm or pulmonary embolism)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-death</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-first cardiovascular event</measure>
    <time_frame>24 weeks maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status: Improvement: patient alive without any cardiovascular event with an improvement of at least one NYHA functional class level; No change: patient alive without any cardiovascular event with stable functional NYHA class</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil + candesartan cilexetil placebo</intervention_name>
    <description>Dosage form: tablet; frequency: daily; duration: 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil placebo + candesartan cilexetil</intervention_name>
    <description>Dosage form: tablets; frequency: daily; duration: 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, adult, out-patients aged between 18 and 85 years

          -  Patients with documented hospital admission within the previous 3 months before
             randomization with discharge diagnosis of CHF

          -  Patients with functional NYHA class II-IV with LVEF &lt; 40% assessed within the last 3
             months

          -  Patients with blood BNP levels &gt; 400 pg/ml or NT-ProBNP levels &gt; 1500 pg/ml

          -  Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy
             (IDC), mitral or aortic insufficiency or hypertension

          -  Patients with stable conventional treatment with diuretics, ACEI and/or beta-blockers
             and/or aldosterone antagonists for at least 2 months prior to randomisation, unless
             documented contraindication or intolerance

        Exclusion Criteria:

          -  Females who are pregnant or plan a pregnancy during the time of the trial, are nursing
             or are of childbearing potential and not using acceptable methods of contraception. If
             a female becomes pregnant during the study, she has to be withdrawn immediately

          -  Patients with current hospitalisation due to heart failure

          -  Patients with stroke or transient ischemic attack (TIA) within the last 3 months

          -  Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass
             or angioplasty within 3 months

          -  Planned cardiac surgery, revascularization or resynchronization within the study
             period

          -  Patients with operable valvular disease or significant obstructive cardiomyopathy

          -  Patients with bradycardia [heart rate (HR) &lt; 50 bpm]

          -  Patients with hypotension [systolic blood pressure (SBP) &lt; 90 mmHg]

          -  Patients with obstructive pneumopathy

          -  Patients with clinical significant renal failure (creatininemia &gt; 200 micromol/l)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lambrecht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ad Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <last_update_submitted>August 6, 2010</last_update_submitted>
  <last_update_submitted_qc>August 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Manager Clinical Development</name_title>
    <organization>Daiichi Sankyo Europe GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

